MVR.F · Medivir AB (publ)

-

Please sign in to comment on MVR.F

1 Comment

Admin

4 years, 1 month ago

Medivir AB (publ) is currently in a long term downtrend where the price is trading 11.3% below its 200 day moving average.

From a valuation standpoint, the stock is 98.7% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 17.2.

Medivir AB (publ)'s total revenue sank by 22.8% to $1M since the same quarter in the previous year.

Its net income has increased by 114.4% to $5M since the same quarter in the previous year.

Finally, its free cash flow grew by 80.7% to $-5M since the same quarter in the previous year.

Based on the above factors, Medivir AB (publ) gets an overall score of 3/5.

Sector	Healthcare
Industry	Biotechnology
Exchange	F
CurrencyCode	EUR
ISIN	SE0000273294

Market Cap	36M
PE Ratio	None
Target Price	None
Dividend Yield	0.0%
Beta	0.35

ABOUT

Medivir AB (publ)

Medivir AB (publ), a pharmaceutical company, focuses on the development and commercialization of treatments for cancer in Nordic region, rest of Europe, and internationally. The company markets Xerclear for the treatment of labial herpes under the Zoviduo name. It is also developing Remetinostat for treating MF cutaneous T-cell lymphoma and basal cell carcinoma, as well as squamous cell carcinoma. In addition, the company is developing MIV-818 for the treatment of liver cancer; MIV-711 to treat osteoarthritis; and Birinapant and IGM-8444 for the treatment of solid tumors, as well as USP-1/TNG348, USP-7, and MBLI/MET-X, which completed preclinical trials for treating cancer and infection. Medivir AB (publ) was incorporated in 1987 and is based in Huddinge, Sweden.

MVR.F · Medivir AB (publ)

-

Medivir AB (publ)

Earnings

Valuation

Cash Flow

Profitability

Performance

Backtest Medivir AB (publ) using a moving average strategy